Accession Number:



Topical Nitric Oxide Therapy to Treat Cervical Neoplasias and Prevent HPV-Associated Cancers

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:


Personal Author(s):

Report Date:


Pagination or Media Count:



The goal of this research is to develop a nitric oxide-releasing vaginal suppository that can be self-administered by female patients as a treatment for cervical neoplasias to eradicate latent HPV-18 infection and inhibit disease progression to cancer. The suppository will contain our proprietary NO-releasing drug, NVN1000, that has been shown to have antiviral efficacy against HPV-18. We have developed five prototype formulations using excipients determined to be compatible with NVN1000 and appropriate analytical methods for determining formulation stability. From the 12 week stability data, we have selected a lead prototype candidate, although it appears refrigeration will be required to maintain stability. Through our collaborator at the University of Alabama Birmingham, we have also established a NVN1000 dose and application frequency that successfully inhibits HPV-18 replication in infected human raft cultures while minimizing cytotoxity.

Subject Categories:

  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

[A, Approved For Public Release]